Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
![PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a33aa443a365c6282bd5449f8899f125cb99c7a9/3-Table3-1.png "PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar")
PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar
Initial Treatment Decisions | Breast Surgery Specialist Melbourne, VIC
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes | Scientific Reports
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC
Scholarly Article or Book Chapter | Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | ID: h989r975x | Carolina Digital Repository
Relazione tra anticipazione diagnostica e terapie: confronto fra cancri della mammella in donne sottoposte e non a screening
ROC curve to determine the best Ki-67 cut-point to differentiate... | Download Scientific Diagram
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer | Scientific Reports
Expression of ER, PR, Her2, and Ki-67 by immunohistochemical staining... | Download Scientific Diagram
The expression of ki-67 by subtypes tumor of breast cancer | Download Scientific Diagram
MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text
The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score - Yang - 2023 - Cancer Medicine - Wiley Online Library
PRISE EN CHARGE DES CANCERS DU SEIN HORMONODÉPENDANTS
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
JPM | Free Full-Text | Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes | springermedizin.de
Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study | PLOS ONE
Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer
Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China - Xue - 2012 - Cancer Science - Wiley Online Library
การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes | Breast Cancer Research and Treatment
Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal
